

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 20, 2023**

**BiomX Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-38762**

(Commission File Number)

**82-3364020**

(I.R.S. Employer  
Identification No.)

**22 Einstein St., Floor 4  
Ness Ziona, Israel**

(Address of Principal Executive Offices)

**7414003**

(Zip Code)

Registrant's telephone number, including area code: **+972 723942377**

**n/a**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Units, each consisting of one share of Common Stock, \$0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock	PHGE.U	NYSE American
Shares of Common Stock, \$0.0001 par value	PHGE	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 20, 2023, BiomX Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders. At the meeting, stockholders voted in favor of all items of business, as indicated below:

***Proposal No. 1-Election of Directors***

The Company’s stockholders voted to elect the following persons to the board of directors of the Company as Class III directors to serve until the 2026 Annual Meetings of Stockholders, respectively:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Dr. Russell Greig	11,855,383	188,098	4,641,670
Jonathan Solomon	11,992,906	50,575	4,641,670
Lynne Sullivan	11,854,073	189,408	4,641,670

***Proposal No. 2-Ratification of Selection of Independent Registered Public Accounting Firm For Fiscal Year 2023***

The Company’s stockholders voted to ratify the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm for the fiscal year ending December 31, 2023.

<b>Voted For</b>	<b>Voted Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
16,462,401	222,000	750	N/A

The results reported above are final voting results.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 20, 2023

**BIOMX INC.**

By: /s/ Jonathan Solomon

Name: Jonathan Solomon

Title: Chief Executive Officer

---